Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin + docetaxel with or without carboplatin for HER2-positive metastatic breast cancer
ACTRN12607000032459Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2002
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab, docetaxel and carboplatin in breast cancer, sponsored by Roche. Primary endpoint: Time to disease progression. Started Oct 2002; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000032459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000032459.